Yes Rak you are correct. But in my mind I see partner shares being offset in some way by upfront cash which would limit our exposure to dilution to some degree and offer clarity and IMO would substantially raise the stock price.
The company needs money to make it to the finish line due to either a corrupt FDA approval process or inept management or a combination of both. I have read some posts about wanting a particular partner to market Afrezza. The only requirement I see is the partner has some sort of presence in PCP and internal medicine practices and deep pockets to market this launch effectively. I could care less who it is if those 2 requirements are met.
